NeoGenomics, Inc. $NEO Stock Holdings Lifted by Aberdeen Group plc

Aberdeen Group plc raised its position in shares of NeoGenomics, Inc. (NASDAQ:NEO) by 91.8% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 792,263 shares of the medical research company’s stock after purchasing an additional 379,165 shares during the period. Aberdeen Group plc owned 0.61% of NeoGenomics worth $6,116,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Headlands Technologies LLC acquired a new position in NeoGenomics in the second quarter worth approximately $32,000. Capstone Financial Advisors Inc. bought a new stake in NeoGenomics in the second quarter worth approximately $73,000. Captrust Financial Advisors acquired a new position in shares of NeoGenomics during the 2nd quarter worth $75,000. Gamco Investors INC. ET AL acquired a new stake in shares of NeoGenomics in the 2nd quarter valued at $80,000. Finally, FORA Capital LLC bought a new stake in NeoGenomics in the second quarter worth $84,000. 98.50% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. Benchmark reissued a “hold” rating on shares of NeoGenomics in a report on Wednesday. Zacks Research upgraded NeoGenomics from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 12th. TD Cowen reaffirmed a “buy” rating on shares of NeoGenomics in a research report on Wednesday, January 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeoGenomics in a research note on Monday, December 29th. Finally, UBS Group reiterated a “hold” rating on shares of NeoGenomics in a research note on Wednesday. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $11.57.

NeoGenomics Stock Performance

Shares of NASDAQ:NEO opened at $9.89 on Friday. The stock has a market capitalization of $1.28 billion, a price-to-earnings ratio of -11.77 and a beta of 1.58. The business’s fifty day moving average price is $12.06 and its two-hundred day moving average price is $10.14. NeoGenomics, Inc. has a fifty-two week low of $4.72 and a fifty-two week high of $13.74. The company has a debt-to-equity ratio of 0.41, a current ratio of 4.26 and a quick ratio of 3.62.

NeoGenomics (NASDAQ:NEO) last issued its earnings results on Tuesday, February 17th. The medical research company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.04 by $0.02. The company had revenue of $190.17 million for the quarter, compared to the consensus estimate of $188.25 million. NeoGenomics had a negative net margin of 14.85% and a negative return on equity of 3.10%. The firm’s revenue for the quarter was up 10.6% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.04 EPS. As a group, analysts predict that NeoGenomics, Inc. will post -0.2 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Alicia C. Olivo sold 20,916 shares of the firm’s stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $12.00, for a total value of $250,992.00. Following the completion of the sale, the executive vice president owned 31,083 shares of the company’s stock, valued at $372,996. This trade represents a 40.22% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, COO Warren Stone sold 22,128 shares of the stock in a transaction on Tuesday, January 20th. The shares were sold at an average price of $12.50, for a total value of $276,600.00. Following the completion of the transaction, the chief operating officer owned 121,631 shares in the company, valued at $1,520,387.50. The trade was a 15.39% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 2.40% of the company’s stock.

About NeoGenomics

NeoGenomics, traded on the Nasdaq under the symbol NEO, is a leading provider of cancer-focused genetic and molecular testing services. Headquartered in Fort Myers, Florida, the company operates an integrated network of CAP-accredited and CLIA-certified laboratories across the United States, Europe and Asia. NeoGenomics delivers diagnostic insights that support oncologists, pathologists and healthcare institutions in the detection, prognosis and treatment of hematologic and solid tumor cancers.

The company’s core service offerings include flow cytometry, immunohistochemistry, fluorescence in situ hybridization (FISH), karyotyping and advanced molecular assays such as next-generation sequencing (NGS) panels and polymerase chain reaction (PCR) tests.